4//SEC Filing
Weyer Christian 4
Accession 0001104659-20-007260
CIK 0001270073other
Filed
Jan 26, 7:00 PM ET
Accepted
Jan 27, 7:01 PM ET
Size
9.3 KB
Accession
0001104659-20-007260
Insider Transaction Report
Form 4
Weyer Christian
EVP Research and Development
Transactions
- Award
Option to Purchase Common Stock
2020-01-23+7,900→ 7,900 totalExercise: $99.66Exp: 2030-01-23→ Common Stock (7,900 underlying) - Award
Common Stock
2020-01-23+4,800→ 18,560 total - Sale
Common Stock
2020-01-27$94.04/sh−723$67,991→ 17,837 total
Footnotes (3)
- [F1]Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2020.
- [F2]This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2020.
Documents
Issuer
INTERCEPT PHARMACEUTICALS, INC.
CIK 0001270073
Entity typeother
Related Parties
1- filerCIK 0001493811
Filing Metadata
- Form type
- 4
- Filed
- Jan 26, 7:00 PM ET
- Accepted
- Jan 27, 7:01 PM ET
- Size
- 9.3 KB